Rona Therapeutics' RN0191 demonstrated up to 95% individual maximum reduction in PCSK9 and up to 74% individual maximum lowering of LDL-C in a Phase 1 trial.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.